Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: WGS

GeneDx Holdings Corp.

Healthcare | Medical - Healthcare Information Services

No licensed closing price on file for WGS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.62

GeneDx Holdings Corp. (NASDAQ: WGS) is a health information company. Figures from SEC EDGAR; updated 2026-10-19 23:21 UTC.

What GeneDx Holdings Corp. does

GeneDx is a genomics company founded to make genetic testing accessible for patients with rare diseases. The company offers exome and genome sequencing tests that have received FDA Breakthrough Device Designation, supported by GeneDx Infinity, a large rare disease dataset. GeneDx provides clinical diagnostic testing, bioinformatics analysis, and variant interpretation services to help clinicians identify genetic causes of disease. The company also supports pharmaceutical discovery and research through its genomic data and analysis capabilities.

Summarized from GeneDx Holdings Corp.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.62
Debt/equity0.41

Revenue, margins & earnings

FY2021: net loss $245M on revenue $212M$212MFY2021FY2022: net loss $549M on revenue $235M$235MFY2022FY2023: net loss $176M on revenue $203M$203MFY2023FY2024: net loss $52M on revenue $305M$305MFY2024FY2025: net loss $21M on revenue $428M$428MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-18
  • 2026-09-18CHIEF FINANCIAL OFFICERSale-541$52.4K
  • 2026-09-18DirectorRestricted Stock UnitOption exercise-1,146—
  • 2026-09-18DirectorOption exercise1,146—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does GeneDx Holdings Corp. do?

GeneDx is a genomics company founded to make genetic testing accessible for patients with rare diseases.

When did WGS last file with the SEC?

GeneDx Holdings Corp.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:21 UTC. This page is also available as JSON at /api/data?ticker=WGS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for WGS and 5,000+ tickers.

Create a free account — keep WGS
For your agent
GET /api/data?ticker=WGS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt